Tandem t:slim Mobile App Now Authorized by Health Canada for iPhone and Android Phones
Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a leading insulin delivery and diabetes technology company, today announced Health Canada authorization for distribution of the Tandem t:slim mobile application for Android and iPhone users. The Tandem t:slim mobile app allows users to deliver a bolus from their compatible smartphone, and to wirelessly upload their pump data to the cloud-based Tandem Source platform.1 The app is expected to be available later this year.
"This authorization demonstrates our dedication to expanding Tandem's global offerings and delivering advanced technology to our Canadian customers," said John Sheridan, president and chief executive officer. "It showcases our team's agility in meeting international standards and our commitment to offering innovative, integrated diabetes solutions."
The Tandem t:slim mobile app is a secure, user-friendly mobile application that, when paired with a t:slim X2 insulin pump, displays the user's pump information on their personal smartphone. In addition to the ability to deliver and cancel a bolus, the mobile app displays the last 24 hours of glucose trends, pump status changes, and insulin therapy data, including basal and bolus deliveries and suspensions of insulin delivery. The app also displays pump alerts and alarms, and it securely uploads data into the cloud-based Tandem Source platform wirelessly. Importantly, the t:slim X2 insulin pump functions independently from the Tandem t:slim mobile app, therefore a user always retains the freedom to view pump therapy data, program requests and cancel or stop bolus insulin requests from their pump.
The Tandem t:slim mobile app will be available for compatible smartphones in the Apple App Store and Google Play store later in 2025. Once available, Tandem will email eligible customers with instructions on how to download and use the app.
1 |
The information on the t:slim mobile app display may not be identical to the current status of the user's pump. Wireless uploads from the t:slim mobile app to the cloud-based Tandem Source platform require a compatible phone and an internet or wireless data connection. Uploads to the Tandem Source platform do not take place in real time and should not be relied upon by healthcare providers or caregivers for remote patient monitoring. Standard carrier data rates may apply. |
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, a global insulin delivery and diabetes technology company, manufactures and sells advanced automated insulin delivery systems that reduce the burden of diabetes management, while creating new possibilities for patients, their loved ones, and healthcare providers. The Company's pump portfolio features the Tandem Mobi system and the t:slim X2 insulin pump, both of which feature Control-IQ advanced hybrid closed-loop technology. Tandem Diabetes Care is based in San Diego, California. For more information, visit tandemdiabetes.com.
Follow @TandemDiabetesCare on TikTok and @TandemDiabetes on Facebook, Instagram, LinkedIn, and X.
Forward-looking Statements
This press release contains both U.S. "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and Canadian "forward-looking information" within the meaning of applicable Canadian securities laws, collectively "forward-looking statements". These forward-looking statements relate to, among other things, the anticipated timing for the Canadian availability of the Tandem t:slim mobile app as well as our ability to provide the Tandem t:slim mobile app on one or both the Apple and Google Play app stores. These and other risks are identified and described in greater detail under the "Risk Factors" heading of our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. Actual results could differ materially from those anticipated or projected in the forward-looking statements. Tandem undertakes no obligation to update or review any forward-looking statement in this press release because of new information, future events, or other factors.
Important Safety Information
This product may not be right for you. Always read the label and follow the directions for use. The t:slim X2 insulin pump is indicated for the treatment of diabetes mellitus in individuals 6 years of age and greater.
The Tandem t:slim mobile app is an accessory intended for use as a connected software device that is able to reliably and securely communicate with compatible insulin pumps, including receiving and displaying pump information and sending insulin delivery commands to a user's connected and compatible t:slim X2 insulin pump.
The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.
© 2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, the Tandem logo, Control-IQ, and t:slim X2 are either registered trademarks or trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. App Store is a registered trademark of Apple Inc. Google Play is a trademark of Google LLC. All other third-party marks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250904665715/en/
Media Contact:
858-366-6900
[email protected]
Investor Contact:
858-366-6900
[email protected]